Swinging for the fences: Long-term survival with ipilimumab in metastatic melanoma

Journal of Clinical Oncology

Volumn 33, Issue 17, 2015, Pages 1873-1877

  Gibney, Geoffrey T ^a   Atkins, Michael B ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B RAF KINASE; CORTICOSTEROID; DABRAFENIB; INTERLEUKIN 2; IPILIMUMAB; LACTATE DEHYDROGENASE; NIVOLUMAB; PEMBROLIZUMAB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; MONOCLONAL ANTIBODY; VINBLASTINE;

ADRENAL INSUFFICIENCY; ARTICLE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; HORMONE SUBSTITUTION; IMMUNOTHERAPY; LACTATE DEHYDROGENASE BLOOD LEVEL; LONG TERM CARE; LONG TERM SURVIVAL; LUNG NODULE; LYMPH NODE DISSECTION; METASTATIC MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STEREOTACTIC RADIOSURGERY; WILD TYPE; ADULT; BRAIN NEOPLASMS; CANCER STAGING; CASE REPORT; CHEMICALLY INDUCED; COMPLICATION; HUMAN; HYPOPITUITARISM; HYPOTHYROIDISM; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MALE; MELANOMA; PARIETAL LOBE; PATHOLOGY; RADIOSURGERY; SECONDARY; SENTINEL LYMPH NODE BIOPSY; SHOULDER; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADRENAL INSUFFICIENCY; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CISPLATIN; DACARBAZINE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOPITUITARISM; HYPOTHYROIDISM; INTERFERON-ALPHA; INTERLEUKIN-2; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA; NEOPLASM STAGING; PARIETAL LOBE; RADIOSURGERY; SENTINEL LYMPH NODE BIOPSY; SHOULDER; SKIN NEOPLASMS; TREATMENT OUTCOME; VINBLASTINE;

EID: 84937156354     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.1807     Document Type: Article

References (32)

1. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116, 1999
2. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166, 2000
3. Atkins MB, Hsu J, Lee S, et al: Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 26:5748-5754, 2008
4. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
5. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
6. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011
7. Margolin K, Ernstoff MS, Hamid O, et al: Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol 13:459-465, 2012
8. Wolchok JD, Hoos A, O'Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15:7412-7420, 2009
9. Schadendorf D, Hodi FS, Robert C, et al: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol [epub ahead of print on February 9, 2015]
10. Robert C, Ribas A, Wolchok JD, et al: Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109-1117, 2014
11. Robert C, Long GV, Brady B, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320-330, 2015
12. Topalian SL, Sznol M, McDermott DF, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020-1030, 2014
13. Weber JS, Kudchadkar RR, Yu B, et al: Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 31:4311-4318, 2013
14. Kluger H, Sznol M, Callahan M, et al: Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). EMSO Congress, Madrid, Spain, September 26-30, 2014 (abstr 10850)
15. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
16. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365, 2012
17. Kefford RF, Maio M, Arance A, et al: Vemurafenib in metastatic melanoma patients with brain metastases: An open-label, single-arm, phase 2, multicenter study. Pigment Cell Melanoma Res 26:965, 2013
18. Long GV, Trefzer U, Davies MA, et al: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087-1095, 2012
19. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAFmutated melanoma. N Engl J Med 367:107-114, 2012
20. Ackerman A, Klein O, McDermott DF, et al: Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 120:1695-1701, 2014
21. Long GV, Stroyakovskiy D, Gogas H, et al: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371:1877-1888, 2014
22. Robert C, Karaszewska B, Schachter J, et al: Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30-39, 2015
23. Larkin J, Ascierto PA, Dŕeno B, et al: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867-1876, 2014
24. Flaherty K, Daud A, Weber JS, et al: Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). J Clin Oncol 32:574s, 2014 (suppl 5s; abstr 9010∧)
25. Kaufman HL, Kirkwood JM, Hodi FS, et al: The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 10:588-598, 2013
26. Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714, 2012
27. McArthur GA, Chapman PB, Robert C, et al: Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323-332, 2014
28. Ascierto PA, Minor DR, Ribas A, et al: Longterm safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763). J Clin Oncol 32:580s, 2014 (suppl 5s; abstr 9034)
29. Hauschild A, Grob JJ, Demidov LV, et al: An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). J Clin Oncol 31:551s, 2013 (suppl 15s; abstr 9013)
30. Flaherty KT, Hennig M, Lee SJ, et al: Surrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trials. Lancet Oncol 15:297-304, 2014
31. Ascierto PA, Simeone E, Sileni VC, et al: Clinical experience with ipilimumab 3 mg/kg: Realworld efficacy and safety data from an expanded access programme cohort. J Transl Med 12:116, 2014
32. Ascierto PA, Simeone E, Sileni VC, et al: Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest 32:144-149, 2014